There’s a shortage of some chemo drugs and antibiotics this year:
More than half the recent shortages have resulted because government or company inspectors found problems like microbial contamination that can be lethal on injection. Others have occurred because of capacity problems at drug plants or lack of interest because of low profits, according to the F.D.A. […] “The race to the bottom has led to an increase of products coming from plants in China and India that may have uncertain supply and may have never been inspected,” Ms. Bresch said. “If the F.D.A. was required to inspect foreign drug plants at the same rate it does domestic ones, we might not have so many of these shortages.”
One example: Johnson & Johnson, whose cancer drug Doxil is in short supply says that “Our third-party manufacturer has had some manufacturing issues related to capacity.” J&J made $2.8 billion last quarter, with a yearly profit margin a bit over 20%, but that’s still not enough.